{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T09:40:22Z","timestamp":1648633222864},"reference-count":56,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1053\/j.seminoncol.2013.01.006","type":"journal-article","created":{"date-parts":[[2013,3,28]],"date-time":"2013-03-28T17:24:50Z","timestamp":1364491490000},"page":"210-217","source":"Crossref","is-referenced-by-count":2,"title":["Managing the Risks of Cardiac Therapy in Cancer Patients"],"prefix":"10.1053","volume":"40","author":[{"given":"Carol L.","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rekha","family":"Parameswaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2013.01.006_bib1","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.critrevonc.2009.11.004","article-title":"Cancer patients with cardiovascular disease have survival rates comparable to cancer patients within the age-cohort of 10 years older without cardiovascular morbidity","volume":"76","author":"Janssen-Heijnen","year":"2010","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib2","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1161\/CIR.0b013e318214876d","article-title":"2011 ACCF\/AHA\/HRS focused updates incorporated into the ACC\/AHA\/ESC 2006 guidelines for the management of patients with atrial fibrillation","volume":"123","author":"Fuster","year":"2011","journal-title":"Circulation"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib3","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/cncr.22434","article-title":"Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes","volume":"109","author":"Sarkiss","year":"2007","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib4","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1161\/01.CIR.105.13.1529","volume":"105","author":"Eagle","year":"2002","journal-title":"Circulation"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib5","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1136\/hrt.2011.224519","article-title":"Non-cardiac surgery in patients with coronary stents: the RECO study","volume":"97","author":"Albaladejo","year":"2011","journal-title":"Heart (British Cardiac Society)"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib6","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ejcts.2006.08.012","article-title":"Perioperative in-stent thrombosis after lung resection performed within 3 months of coronary stenting","volume":"30","author":"Brichon","year":"2006","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d4588","article-title":"Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis","volume":"343","author":"Bauer","year":"2011","journal-title":"BMJ"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib8","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1111\/j.1538-7836.2011.04456.x","article-title":"Management of patients with recently implanted coronary stents on dual antiplatelet therapy who need to undergo major surgery","volume":"9","author":"Savonitto","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib9","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.jacc.2012.04.062","article-title":"The risk of adverse cardiac and bleeding events following noncardiac surgery relative to antiplatelet therapy in patients with prior percutaneous coronary intervention","volume":"60","author":"Singla","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib10","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib11","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1345\/aph.1Q290","article-title":"Transient elevation of international normalized ratio during cisplatin-based chemotherapy in patients who are taking warfarin","volume":"45","author":"Yano","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib12","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.clinthera.2008.06.008","article-title":"Probable interaction between warfarin and antitumor agents used in R-ESHAP chemotherapy","volume":"30","author":"Suzuki","year":"2008","journal-title":"Clin Ther"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/bmj.298.6666.93","article-title":"Life threatening interaction between tamoxifen and warfarin","volume":"298","author":"Tenni","year":"1989","journal-title":"BMJ"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib14","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1345\/aph.1M176","article-title":"Safety of concomitant tamoxifen and warfarin","volume":"43","author":"Givens","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib16","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1179\/joc.2006.18.4.421","article-title":"Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients","volume":"18","author":"Boruban","year":"2006","journal-title":"J Chemother"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib17","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1592\/phco.30.12.1259","article-title":"Comparison of the 5-fluorouracil-warfarin and capecitabine-warfarin drug interactions","volume":"30","author":"Shah","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib18","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.thromres.2012.08.290","article-title":"Long-term treatment of venous thromboembolism with tinzaparin compared to vitamin K antagonists: a meta-analysis of 5 randomized trials in non-cancer and cancer patients","volume":"130","author":"Laporte","year":"2012","journal-title":"Thromb Res"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib19","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.thromres.2008.09.002","article-title":"Efficacy of low- molecular-weight-heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials","volume":"123","author":"Louzada","year":"2009","journal-title":"Thromb Res"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib20","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib21","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib22","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib23","doi-asserted-by":"crossref","first-page":"758385","DOI":"10.1155\/2012\/758385","article-title":"Management of venous thromboembolism in patients with advanced gastrointestinal cancers: what is the role of novel oral anticoagulants?","volume":"2012","author":"Martin","year":"2012","journal-title":"Thrombosis"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib24","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1200\/JCO.2009.22.3958","article-title":"Anticoagulation in the treatment of established venous thromboembolism in patients with cancer","volume":"27","author":"Lee","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib25","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/ajh.23122","article-title":"Cancer patients requiring interruption of long-term warfarin because of surgery or chemotherapy induced thrombocytopenia: the use of fixed sub-therapeutic doses of low-molecular weight heparin","volume":"87","author":"Saccullo","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib26","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib27","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ahj.2005.04.017","article-title":"Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF)","volume":"151","author":"Gage","year":"2006","journal-title":"Am Heart J"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib28","doi-asserted-by":"crossref","first-page":"JC4","DOI":"10.7326\/0003-4819-157-8-201210160-02013","article-title":"Various risk stratification schemes predict ischemic stroke and bleeding in atrial fibrillation","volume":"157","author":"Gage","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib29","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib30","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jacc.2011.03.031","article-title":"A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study","volume":"58","author":"Fang","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib31","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jacc.2012.06.019","volume":"60","author":"Apostolakis","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib32","doi-asserted-by":"crossref","first-page":"6C","DOI":"10.1016\/j.amjcard.2005.12.006","article-title":"Statin safety: an overview and assessment of the data\u20142005","volume":"97","author":"Bays","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib33","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.ahj.2003.12.037","article-title":"Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors","volume":"147","author":"Jamal","year":"2004","journal-title":"Am Heart J"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib34","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib35","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1023\/A:1011036428972","article-title":"HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein","volume":"18","author":"Wang","year":"2001","journal-title":"Pharm Res"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib36","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/sj.bjc.6601152","article-title":"Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia","volume":"89","author":"O'Brien","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib37","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1182\/blood-2010-07-294330","article-title":"Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib","volume":"117","author":"Haouala","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib38","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ctrv.2009.08.004","article-title":"Clinical pharmacokinetics of tyrosine kinase inhibitors","volume":"35","author":"van Erp","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib39","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/j.1365-2125.2008.03150.x","article-title":"Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia","volume":"65","author":"Wang","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib40","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management","volume":"53","author":"Yeh","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib41","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/eurheartj\/ehs257","article-title":"Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice","volume":"33","author":"Zannad","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib42","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib43","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1524-6175.2004.3735.x","article-title":"Gynecomastia and antihypertensive therapy","volume":"6","author":"Mosenkis","year":"2004","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib45","doi-asserted-by":"crossref","first-page":"e4447","DOI":"10.1136\/bmj.e4447","article-title":"Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study","volume":"345","author":"Mackenzie","year":"2012","journal-title":"BMJ"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib46","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/oxfordjournals.aje.a113416","article-title":"Nonestrogenic drugs and breast cancer","volume":"116","author":"Danielson","year":"1982","journal-title":"Am J Epidemiol"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib47","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/0022-4731(88)90295-6","article-title":"Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture","volume":"31","author":"Luthy","year":"1988","journal-title":"J Steroid Biochem"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib48","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.11.2011.5238","article-title":"Spironolactone, a possible selective androgen receptor modulator, should be used with caution in patients with metastatic carcinoma of the prostate","volume":"2012","author":"Sundar","year":"2012","journal-title":"BMJ Case Rep"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib49","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1158\/0008-5472.CAN-11-3980","article-title":"Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100","volume":"72","author":"Richards","year":"2012","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib50","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib51","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1200\/JCO.2009.25.9259","article-title":"Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer","volume":"28","author":"Danila","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib52","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","article-title":"Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven","volume":"26","author":"Attard","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib53","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1200\/JCO.2009.24.1281","article-title":"Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy","volume":"28","author":"Ryan","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib54","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2205","article-title":"Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case-control study","volume":"10","author":"Ahern","year":"2008","journal-title":"Breast Cancer Res"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib55","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2010.32.8146","article-title":"Digoxin use and the risk of breast cancer in women","volume":"29","author":"Biggar","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib56","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1751-7133.2010.00161.x","article-title":"Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT)","volume":"16","author":"Butler","year":"2010","journal-title":"Congest Heart Fail"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib57","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/FTD.0b013e31815c16f5","article-title":"Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring","volume":"29","author":"Zhou","year":"2007","journal-title":"Ther Drug Monit"},{"key":"10.1053\/j.seminoncol.2013.01.006_bib58","series-title":"Cytochrome P450 enzymes: substrates, inhibitors, and inducers (pharmacogenomics)","year":"1978"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775413000079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775413000079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T16:26:17Z","timestamp":1539793577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775413000079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0093775413000079"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2013.01.006","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}